Lime Therapeutics uses its proprietary LipidSense™ platform, an ultrasensitive high‑throughput system that quantifies lysosomal lipid flux in real time in live cells, large‑scale screens, and whole‑animal models. The technology enables pharmaceutical and biotech R&D teams to discover and validate lipid‑focused therapeutic targets for oncology, cardiometabolic, lysosomal storage, and neurodegenerative diseases, accelerating the development of precision medicines that modulate aberrant lipid metabolism.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Lipid metabolism dysregulation underlies many cancers, cardiometabolic disorders, lysosomal storage diseases, and neurodegenerative conditions, yet existing drug discovery tools lack the sensitivity and throughput to identify and validate lipid‑focused therapeutic targets.
Solution
Limetherapeutics addresses this gap with its proprietary LipidSense™ platform, an ultrasensitive, high‑throughput system that quantifies lysosomal lipid flux in real time across live cells, large‑scale screens, and whole‑animal models. By delivering rapid readouts of how candidate compounds modulate lipid pathways, the platform enables systematic discovery of drugs that either restrict tumor lipid access or restore normal lysosomal lipid handling in metabolic and neurodegenerative diseases. The technology integrates optical nanoreporters based on single‑walled carbon nanotubes, providing quantitative, live‑cell imaging of lipid dynamics without disrupting cellular physiology. Results are fed into a discovery pipeline that prioritizes targets for preclinical development, accelerating the translation of lipid‑modulating mechanisms into precision medicines.
Target Audience
Primary customers are pharmaceutical and biotech R&D teams focused on target discovery and early‑stage drug development for lipid‑related pathways in oncology, metabolic, lysosomal storage, and neurodegenerative disease programs.
Features
- Real‑time optical nanoreporter that measures endolysosomal lipid flux with sub‑second resolution
- Scalable high‑throughput screening compatible with standard assay formats and live‑animal studies
- Live‑cell compatibility preserves physiological context while delivering quantitative lipid readouts
- Integrated data analytics pipeline for rapid hit identification and target validation
- Platform‑agnostic workflow that can be applied to oncology, cardiometabolic, lysosomal storage, and neurodegenerative programs